OrbiMed’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

OrbiMed’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,621,443	Closed	-$39.5M	–	153
2017 Q3	$39.5M	Sell	13,621,443 -7,531,900	-36%	-$25.7M	0.38%	69
2017 Q2	$94.1M	Hold	21,153,343	–	–	0.99%	29
2017 Q1	$98.6M	Buy	21,153,343 +2,911,945	+16%	+$16.9M	1.12%	30
2016 Q4	$111M	Buy	18,241,398 +12,264,750	+205%	+$64.1M	1.42%	24
2016 Q3	$32.9M	Hold	5,976,648	–	–	0.38%	62
2016 Q2	$22.7M	Buy	5,976,648 +3,700,000	+163%	+$12.5M	0.24%	71
2016 Q1	$6.28M	Hold	2,276,648	–	–	0.07%	109
2015 Q4	$12.9M	Hold	2,276,648	–	–	0.12%	84
2015 Q3	$12.1M	Sell	2,276,648 -844,500	-27%	-$6.54M	0.12%	87
2015 Q2	$25.9M	Hold	3,121,148	–	–	0.22%	75
2015 Q1	$14.4M	Buy	+3,121,148	New	+$10.1M	0.12%	90

Other funds holding SGYP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OrbiMed's SGYP Position: Q4 2017 in Review

OrbiMed sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q4 2017, closing a stake of 13,621,443 shares — an estimated $39.5M sold.

OrbiMed first reported a position in SGYP in Q1 2015 and held it in 11 quarters. The position peaked at $111M in Q4 2016. 149 funds tracked by Wall St. Rank hold SGYP as of Q4 2017.

OrbiMed reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q4 2017 after selling out during the quarter.
OrbiMed sold 13,621,443 Synergy Pharmaceuticals, Inc Common Stock shares in Q4 2017, an estimated $39.5M.
OrbiMed first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2015 and held it in 11 quarters.
OrbiMed's Synergy Pharmaceuticals, Inc Common Stock position peaked at $111M in Q4 2016.
149 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.